Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction-Reference-Cited by-同舟云学术

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

Published:2015-03-19 Issue:12 Volume:125 Page:1932-1935
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Rawstron Andy C.¹,Gregory Walter M.²,de Tute Ruth M.¹,Davies Faith E.³,Bell Sue E.²,Drayson Mark T.⁴,Cook Gordon¹,Jackson Graham H.⁵,Morgan Gareth J.³,Child J. Anthony²,Owen Roger G.¹

Affiliation:

1. St James's University Hospital, Leeds, United Kingdom;

2. University of Leeds, Leeds, United Kingdom;

3. Institute of Cancer Research, London, United Kingdom;

4. University of Birmingham, Birmingham, United Kingdom; and

5. University of Newcastle, Newcastle, United Kingdom

Abstract

Key Points The level of MRD quantified by flow cytometry is more informative than a 0.01% threshold and independently predicts OS. There was approximately 1 year survival benefit per log depletion. A lower cut point for predicting improved outcome was not reached.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/125/12/1932/1383590/1932.pdf

Reference13 articles.

1. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma.;Paiva;Blood,2012

2. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.;Paiva;Blood,2008

3. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.;Rawstron;J Clin Oncol,2013

4. Minimal residual disease in multiple myeloma.;Munshi;J Clin Oncol,2013

5. Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium.;Landgren;Am J Hematol,2014

Cited by 155 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group;Cancers;2024-02-29

2. Role of minimal residual disease assessment in multiple myeloma;Haematologica;2024-02-08

3. Plasma Cell Dyscrasias;Tata Memorial Centre Textbook of Oncology;2024

4. Modern approaches to assessment of minimal residual disease in multiple myeloma (plasma cell myeloma) cases;Medicine of Extreme Situations;2023-12

5. Circulating tumor DNA and bone marrow minimal residual disease negativity confers superior outcome for multiple myeloma patients;Haematologica;2023-09-28